Home » Stocks » VTVT

vTv Therapeutics Inc. (VTVT)

Stock Price: $2.27 USD -0.04 (-1.73%)
Updated May 13, 2021 4:00 PM EDT - Market closed
After-hours: $2.25 -0.02 (-0.88%) May 13, 7:54 PM
Market Cap 186.34M
Revenue (ttm) 7.39M
Net Income (ttm) -8.02M
Shares Out 80.64M
EPS (ttm) -0.18
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 13
Last Price $2.27
Previous Close $2.31
Change ($) -0.04
Change (%) -1.73%
Day's Open 2.35
Day's Range 2.24 - 2.36
Day's Volume 1,063,659
52-Week Range 1.44 - 4.75

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

vTv Therapeutics (VTVT) delivered earnings and revenue surprises of -50.00% and 23.38%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

1 week ago - Zacks Investment Research

Awarded Breakthrough Therapy designation for TTP399 for the treatment of type 1 diabetes

1 week ago - GlobeNewsWire

vTv Therapeutics, Arrival, PubMatic, and Schrodinger are four up-and-coming stocks to buy. All four are benefiting from rapidly shifting trends.

Other stocks mentioned: ARVL, PUBM, SDGR
2 weeks ago - InvestorPlace

The FDA bestows a Breakthrough Therapy designation to vTv Therapeutics' (VTVT) TTP399 as an adjunctive therapy to insulin for treating type I diabetes. Shares rise.

4 weeks ago - Zacks Investment Research

Today, VTVT stock is on the move as investors price in a key announcement from the FDA designating a leading drug a breakthrough therapy. The post VTVT Stock: The FDA News Sending vTv Therapeutics Soari...

1 month ago - InvestorPlace

Designation offers potential for expedited development pathway and reinforces TTP399's potential to provide a substantial clinical benefit Designation offers potential for expedited development pathway ...

1 month ago - GlobeNewsWire

HIGH POINT, N.C., April 12, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc.  (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for typ...

1 month ago - GlobeNewsWire

Claims cover methods of reducing HbA1c and the incidence of hypoglycemia using TTP399 in patients with type 1 diabetes Claims cover methods of reducing HbA1c and the incidence of hypoglycemia using TTP3...

1 month ago - GlobeNewsWire

HIGH POINT, N.C., March 18, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc.  (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for typ...

1 month ago - GlobeNewsWire

HIGH POINT, N.C., March 08, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc.  (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for typ...

2 months ago - GlobeNewsWire

Initiation of Mechanistic Study of TTP399 expected during Q1 2021

2 months ago - GlobeNewsWire

Results found a clinically meaningful decrease in frequency of severe and symptomatic hypoglycemia in addition to statistically significant reductions in HbA1c Results found a clinically meaningful decr...

2 months ago - GlobeNewsWire

Phase 1 multiple ascending dose study to evaluate safety of HPP737 in healthy volunteers and inform dose selection for phase 2 planned for 2H 2021

2 months ago - GlobeNewsWire

HIGH POINT, N.C., Jan. 06, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc.  (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for type...

4 months ago - GlobeNewsWire

HIGH POINT, N.C., Dec. 15, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc.  (Nasdaq: VTVT) today announced that the Phase 2 Elevage study of azeliragon in people with mild Alzheimer's disease and type 2 ...

4 months ago - GlobeNewsWire

Eli Lilly (NYSE: LLY) shares are trading higher on Tuesday after the company announced it will acquire Prevail for total consideration of $26.50 per share in cash. The company also issued the fiscal yea...

Other stocks mentioned: MESO, AVXL, BNTX, LLY
4 months ago - Benzinga

HIGH POINT, N.C., Dec. 15, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq:VTVT) today announced that vTv Therapeutics LLC (“vTv”) has entered into a licensing agreement with Anteris Bio for worl...

4 months ago - GlobeNewsWire

Tv Therapeutics (NASDAQ: VTVT) shares were trading higher on Friday after the company said its Phase 2 Simplici-T1 study of TTP399 achieved the primary objective of a statistically significant reduction...

Other stocks mentioned: SLDB, SLS
5 months ago - Benzinga

Shares of VTVT stock are taking off on Friday after vTv Therapeutics' parent company purchased 625,000 shares for $1.60 per share. The post VTVT Stock: Why vTv Therapeutics Is Soaring on Friday appeared...

5 months ago - InvestorPlace

As of late, it has definitely been a great time to be an investor in vTv Therapeutics (VTVT).

5 months ago - Zacks Investment Research

The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We have processed the filings of the more than 817 ...

5 months ago - Insider Monkey

HIGH POINT, N.C., Nov. 24, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) today announced it has entered into a common stock purchase agreement (“Purchase Agreement”) for up to $47 millio...

5 months ago - GlobeNewsWire

With the pandemic drawing much attention toward biotech stocks, there are some interesting ideas among in the small-cap field, but only if you understand the severe risks involved. The post 7 Biotech Pe...

Other stocks mentioned: CANF, FPRX, GTBP, IFRX, TNXP, VXRT
6 months ago - InvestorPlace

HIGH POINT, N.C., Nov. 05, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the third quarter ended September 30, 2020, and provided an update on the pro...

6 months ago - GlobeNewsWire

HIGH POINT, N.C., Nov. 04, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) today reported baseline characteristics for the enrolled subjects in the ongoing Elevage clinical study of azelir...

6 months ago - GlobeNewsWire

HIGH POINT, N.C., Oct. 29, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) today announced that it will make an oral presentation at the 13th Clinical Trials on Alzheimer's Disease (CTAD) ...

6 months ago - GlobeNewsWire

Data Reported at EASD Virtual Conference Demonstrate that TTP399 Did Not Increase Plasma or Urine Ketones, Avoiding a Key Limitation to the Development of Oral Adjunctive Therapies for T1D Data Reported...

7 months ago - GlobeNewsWire

HIGH POINT, N.C., Sept. 15, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc.  (Nasdaq: VTVT) announced the appointment of Edward P. Taibi, Executive Vice President of MacAndrews & Forbes Incorporated (...

7 months ago - GlobeNewsWire

A handful of pharmaceutical stocks have been on fire lately, but I'm writing for a "buy" prescription for five of the best names now.

Other stocks mentioned: GILD, REGN, TAK, ZTS
8 months ago - InvestorPlace

HIGH POINT, N.C., Aug. 03, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the second quarter ended June 30, 2020, and provided an update on the pro...

9 months ago - GlobeNewsWire

HIGH POINT, N.C., July 27, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc . (Nasdaq: VTVT) today announced that the Company will present at the upcoming 2020 Alzheimer's Association International Con...

9 months ago - GlobeNewsWire

- Treatment with TTP399 resulted in significant improvements in HbA1c with reduction in insulin, without increasing risk of hypoglycemia or diabetic ketoacidosis (DKA) -

11 months ago - GlobeNewsWire

HIGH POINT, N.C., May 22, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq:VTVT) today announced that it will host its 2020 Annual Meeting of Stockholders (the "Annual Meeting") as a virtual-o...

11 months ago - GlobeNewsWire

Is (VTVT) Outperforming Other Medical Stocks This Year?

1 year ago - Zacks Investment Research

As of late, it has definitely been a great time to be an investor in vTv Therapeutics Inc. (VTVT).

1 year ago - Zacks Investment Research

Company Announced Positive Results from Its Phase 2 Type 1 Diabetes Trial Showing that TTP399 Lowered HbA1C, Decreased the Use of Insulin for Patients and Increased Time in Range Company Announced Posit...

1 year ago - GlobeNewsWire

Steve Holcombe transitioned from telecom to biotech back when vTv Therapeutics Inc (NASDAQ: VTVT) was just a startup.

1 year ago - Benzinga

vTv Therapeutics: A Promising Small Molecule Drug Discovery Pick For 2020

1 year ago - Seeking Alpha

Let us take a look at some drug/biotech stocks that are poised to beat on earnings in the fourth quarter.

Other stocks mentioned: CLVS, ETON, IMMU, PRGO
1 year ago - Zacks Investment Research

Shares of micro-cap biotech vTv Therapeutics Inc (NASDAQ: VTVT) were advancing to their highest level since October 2018 Monday following a clinical readout from the company.

1 year ago - Benzinga

These drug stocks all have tremendous potential as these small companies work to treat widespread diseases in the U.S. and beyond.

Other stocks mentioned: GWPH, MRNA
1 year ago - InvestorPlace

vTv Therapeutics (VTVT) delivered earnings and revenue surprises of 9.09% and -99.53%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

Here we discuss six small-cap companies with promising candidates in their pipeline for Alzheimer's disease.

Other stocks mentioned: ACIU, ITCI
1 year ago - Zacks Investment Research

Patients treated with TTP399 had improved Time in Range (TIR), reduced time in hyperglycemia, fewer hypoglycemic events, and lower bolus insulin dose Patients treated with TTP399 had improved Time in Ra...

1 year ago - GlobeNewsWire

The thinly traded micro-cap biotech vTv Therapeutics Inc (NASDAQ: VTVT) is on investors' radars ahead of a Sept.

1 year ago - Benzinga

 Presenting New Clinical Data from Phase 2 Study in Type 1 Diabetes with Liver Selective GKA Program

1 year ago - GlobeNewsWire

HIGH POINT, N.C., Sept. 04, 2019 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for...

1 year ago - GlobeNewsWire

The GuruFocus All-in-One Screener can be used to find insider trades from the past week.

Other stocks mentioned: AMAG, ARES, RP, RUN, WHF
1 year ago - GuruFocus

vTv Therapeutics is currently trading at a super low stock price, indicating a potential buy for a high risk/return.

1 year ago - Seeking Alpha

About VTVT

vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers, develops, and sells orally administered small molecule drug candidates to fill unmet medical needs. The company is developing TTP399, an orally administered, small molecule, liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant PDE4 inhibitor that addresses inflammatory diseases. It is also involved in the clinical development of other programs, including a small molecule GLP-1r agonist; the PD... [Read more...]

Industry
Biotechnology
IPO Date
Jul 30, 2015
CEO
Stephen Holcombe
Employees
25
Stock Exchange
NASDAQ
Ticker Symbol
VTVT
Full Company Profile

Financial Performance

In 2020, VTVT's revenue was $6.41 million, an increase of 132.05% compared to the previous year's $2.76 million. Losses were -$8.50 million, -34.84% less than in 2019.

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for VTVT stock is "Buy." The 12-month stock price forecast is 6.75, which is an increase of 197.36% from the latest price.

Price Target
$6.75
(197.36% upside)
Analyst Consensus: Buy